Only MCED test on-market to analyze multiple biomarker classes, enhancing early cancer detection-Offered as a laboratory-developed test at ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced performance data for its blood-based colorectal cancer ...

An updated version of Exact Sciences’ stool-based colorectal cancer screening test detected cancer accurately in a massive study, triggering fewer false alarms than its current product, the company ...

Shares of Exact Sciences (NASDAQ:EXAS) gained on Wednesday after the maker of the Cologuard stool-based cancer test announced plans to release data from a blood-based cancer test on Sept. 16. At Baird ...

MADISON, Wis., Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present late-breaking ...

Exact Sciences has unveiled new findings from a case-control study demonstrating the potential of its advanced multi-biomarker class approach to improve early-stage and overall cancer detection. The ...

Exact Sciences Corp. reported performance data for its blood-based colorectal cancer screening test that showed sensitivities of 88.3% for CRC and 31.2% for advanced precancerous lesions at ...

MADISON, Wis., Dec. 9, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today shared initial clinical validation data for its ...